These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
    Author: Nichols CN, Bernal I, Prince AM, Andrus L.
    Journal: AIDS Res Hum Retroviruses; 2002 Jan 01; 18(1):49-56. PubMed ID: 11804556.
    Abstract:
    The objective of this study was to compare the virus-neutralizing ability of two different preparations of HIV immune globulin (HIVIG) isolated from human plasma units that were selected according to two different criteria. The first preparation, designated NYBC-HIVIG, was isolated from plasmas with high neutralizing antibody titers against HIV-1. The second preparation, designated NABI-HIVIG, was isolated from plasma with high titers of antibody to the HIV-1 p24 antigen. A panel of primary HIV-1 isolates was phenotypically characterized by their ability to induce syncytia in CEM-SS cells. Neutralization of this panel of primary isolates by the two HIVIG preparations was assessed in HeLa-MAGI-CCR5 cells, utilizing a luminescence-based assay. In addition, the reactivities of these two preparations with a panel of HIV-1 gp120 proteins, V3 loop peptides, and HIV-1 p24 antigen were determined. Both HIVIG preparations were shown to neutralize all virus isolates tested. However, doses of NABI-HIVIG required for 50% virus neutralization were 2.2- to 4.4- fold (mean, 3.2-fold) higher than the required doses of NYBC-HIVIG. Comparative antigen-binding assays showed that, although NABI-HIVIG possessed higher titers of antibody to HIV-1 p24, NYBC-HIVIG generally contained higher titers of antibody to HIV-1 gp120 and V3 peptides. These experiments show that the criteria used for selection of source plasmas for isolation of HIVIG can influence the effective concentration of virus-neutralizing antibody present in the final immunoglobulin preparation, and may determine the doses required for clinical efficacy.
    [Abstract] [Full Text] [Related] [New Search]